PsoProtect is an international registry developed to enable clinicians to report outcomes of COVID-19 in individuals with psoriasis. It is hoped that PsoProtect will help us to understand how immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis and it will provide real-time updates on cases reported for the benefit of the dermatology community. PsoProtect seeks to improve our understanding of how factors such as immunomodulator therapies and comorbidities impact outcomes to COVID-19 in psoriasis.
IPC is pleased to be part of this important initiative and asks if you have a psoriasis patient diagnosed with COVID-19, please contribute to this important registry by submitting your case using the online PsoProtect case report form.
In addition, an adjoining registry PsoProtectMe has been set up for patients to self-report their experiences.
View the current data. You can also view our summary of the data collected from the first 50 cases, 200 cases, 1002 cases, 1118 cases.
WATCH NOW Catherine Smith, MD, and Savteer Mahil, MD, talk to IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD, about their goals for the PsoProtect patient registry to study COVID-19 and psoriasis.
Latest news PsoProtect Registry Data UpdateSeptember 13, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1,205 cases. July Update on PsoProtect Registry DataJuly 12, 2021Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1,147 cases. Expert Opinion: Coronavirus disease 2019 (COVID‐19)‐associated hospitalization and mortality in patients with psoriasis: A population‐based studyJuly 07, 2021IPC Councilor, Luigi Naldi, MD, shares his expert opinion on a population-based study of COVID-19 - associated hospitalization and mortality in patients with psoriasis. Grand Rounds tutorial on IPC's psoriasis severity reclassificationJune 21, 2021The AbbVie program features IPC Board Member Bruce Strober’s Grand Rounds, a tutorial explaining the current method of measuring the severity of psoriasis, why this limits proper care and treatment for psoriasis patients, how IPC’s Disease Severity Reclassification Project solves these problems, and how clinicians can implement this new classification method. More News
